Two Sigma Advisers LP Sells 11,100 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Two Sigma Advisers LP trimmed its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 13.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 73,900 shares of the company’s stock after selling 11,100 shares during the quarter. Two Sigma Advisers LP owned about 0.16% of Y-mAbs Therapeutics worth $579,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in YMAB. SG Americas Securities LLC grew its position in Y-mAbs Therapeutics by 30.7% during the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after buying an additional 4,163 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Y-mAbs Therapeutics by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock valued at $2,228,000 after purchasing an additional 4,963 shares during the last quarter. AlphaQuest LLC raised its position in Y-mAbs Therapeutics by 6,911.6% during the 4th quarter. AlphaQuest LLC now owns 27,135 shares of the company’s stock valued at $212,000 after purchasing an additional 26,748 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics during the 4th quarter valued at approximately $46,000. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on YMAB. Oppenheimer decreased their target price on Y-mAbs Therapeutics from $20.00 to $15.00 and set an “outperform” rating for the company in a research report on Thursday, May 29th. Bank of America downgraded Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research note on Tuesday, April 22nd. Wedbush reiterated an “outperform” rating and set a $18.00 target price (down from $21.00) on shares of Y-mAbs Therapeutics in a research note on Wednesday, May 28th. HC Wainwright dropped their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Finally, Truist Financial decreased their target price on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Two investment analysts have rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.60.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares of the company’s stock, valued at $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 22.50% of the stock is currently owned by insiders.

Y-mAbs Therapeutics Trading Up 2.7%

Shares of YMAB stock opened at $4.87 on Wednesday. The stock has a market capitalization of $220.53 million, a price-to-earnings ratio of -9.02 and a beta of 0.53. Y-mAbs Therapeutics, Inc. has a 12-month low of $3.55 and a 12-month high of $16.11. The stock’s 50-day moving average price is $4.36 and its 200-day moving average price is $6.24.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. As a group, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.